Please login to the form below

Not currently logged in

Kala names Howard Rosen as chairman

He is former CEO of Pearl Therapeutics and VP at Gilead
Howard Rosen, Kala

Kala Pharmaceuticals has appointed life sciences industry veteran Howard Rosen as chairman of the board of directors.

Rosen has held several senior roles at major biotechs, including his current positions on the board of directors at AcelRX, Aldea, Entrega and PaxVax, where he is also chairman.

His non-board experience includes serving as president and CEO of Pearl Therapeutics, which was acquired by AstraZeneca last year in a deal worth up to $1.15bn, as well as a period as VP, commercial strategy at Gilead Sciences and president of Johnson & Johnson subsidiary ALZA Corporation.

Kala's president and CEO Guillaume Pfefer commented on this rich experience when welcoming Rosen.

“Howard's extensive track record of building and guiding successful companies will be extremely helpful to Kala at this critical juncture as we advance a rich pipeline of ophthalmology product candidates into clinical development,” said Pfefer, who joined the eyecare specialist from Sanofi in 2012.

8th January 2014

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Digital health
The untapped potential to transform healthcare...
When is it time to rebrand?
The Biosimilar Challenge